Intercytex announces introduction of Vavelta at FACE - the UK’s largest medical aesthetic conference
2nd July 2007
Cambridge, UK: Intercytex Group plc, the cell therapy company focused on aesthetic medicine and tissue repair, announces that it has introduced VAVELTA, its facial rejuvenation product, for the first time at the Facial Aesthetic Conference and Exhibition (FACE) held from 29th June to 1st July in London. FACE is the largest medical aesthetic conference in the UK for practitioners and clinics that deliver predominantly non-surgical medical aesthetic treatments.
VAVELTA is on track for launch in the second half of 2007 and will be launched initially with a selected group of physicians who have significant experience in the use of cell therapy for facial rejuvenation. It is expected that the first VAVELTA practitioners will be announced shortly.
Intercytex’ stand at FACE focused on the use and underlying science of cell therapy in aesthetic medicine. It was supported by a presentation given to conference delegates by Dr Paul Kemp, Intercytex’ Chief Scientific Officer, entitled ‘From cells to cell therapy’.
VAVELTA incorporates the same cells, allogeneic human fibroblasts, as used in two other Intercytex products in development - ICX-SKN (skin graft replacement) and ICX-PRO (chronic wound healing).
Nick Higgins, Intercytex’ CEO, said: “We are very pleased to have commenced the launch phase of VAVELTA. This represents the culmination of a considerable effort to complete the development of VAVELTA, a novel facial rejuvenation product which we will believe will make a considerable impact in the rapidly expanding aesthetic medicine market.”